Walter M. Stadler to Immunoconjugates
This is a "connection" page, showing publications Walter M. Stadler has written about Immunoconjugates.
Connection Strength
0.128
-
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016 Jan; 77(1):155-62.
Score: 0.128
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.